Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FOB debate awaits Kennedy/Enzi bill

Executive Summary

Rep. Henry Waxman's follow-on biologics bill arrives in the Senate March 26, courtesy of Chuck Schumer, D-N.Y., as S. 726, with three Republican and four Democrat co-sponsors, including Schumer. Meanwhile, Waxman is now joined by two Democrats and four Republicans in backing H.R. 1427. This compares to 54 co-sponsors signing on to Rep. Anna Eshoo's H.R. 1548 (1"The Pink Sheet" DAILY, March 18, 2009). Biosimilars legislation reported by the Senate Health, Education, Labor and Pensions Committee in 2008 will be re-introduced by Sens. Ted Kennedy, D-Mass., and Michael Enzi, R-Wyo., as soon as an agreement is reached on language to clarify how biologics can be modified and still qualify as innovative and gain 12 years of data exclusivity

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS050878

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel